Halberd Enters Strategic Alliance for Longevity, Alzheimer’s Disease, and Cancer Early Detection, Prevention and Treatment
Jackson Center, PA, September 27, 2022 – Halberd Corporation (OTC-PINK: "HALB”) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named “ExtendalifeTM”. The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer’s Disease and Cancer treatments using the combined patented and patent-pending technologies of the alliance member companies. The subsidiary will be staffed ...
Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein
Jackson Center, PA, August 23, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have demonstrated the ability to precisely control the level of PD-1 in human blood serum in laboratory in-vitro testing. PD-1 (programmed cell death–1) is a T-Cell protein which can be used by tumor cells to fool the body’s immune system into allowing the tumor to grow[1]. Halberd’s extracorporeal process, operating on blood serum, can potentially be used to eliminate PD-1 and allow the ...
NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology
Jackson Center, PA, August 04, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has received a letter of endorsement from Carl Eller, President of the NFL Retired Players Association (NFL RPA), for Halberd’s research work in the development of treatments for Traumatic Brain Injury (TBI)/chronic traumatic encephalopathy (CTE) sustained by current and retired players. Traumatic brain injuries often progress to neurodegenerative diseases, such as PTSD, Alzheimer’s Disease, Parkinson’s Disease, Epilepsy and suicide ideation. The letter of endorsement ...
Halberd Corp. Launches “Halberd Cancer Therapeutics, LTD” Wholly Owned Subsidiary
Jackson Center, PA, July 20, 2022 – Halberd Corporation (OTC-PINK: "HALB”) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberd’s patented extracorporeal technology has demonstrated the capacity for successful application to a wide variety of diseases and health-related illnesses. For now, the new entity will be staffed by Halberd personnel until such time as business opportunities arise and appropriately skilled individuals are recruited to carry the subsidiary forward in its ...
Halberd’s Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron
Boosts Effectiveness of Commercial Covid Antibodies by 45% Jackson Center, PA, July 14, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers developed, with appropriate protocols, a SARS-CoV-2 antibody effective against all four Covid-19 mutations currently in circulation, including Omicron. When Halberd’s antibody was combined with a leading commercially available Covid-19 antibody in an antibody cocktail, effectiveness of the commercial antibody was increased from 65% to 94%. This could lead to a treatment that is widely effective ...
Halberd Corporation Update, CEO Letter and 2022 Expectations
Q2 Accomplishments and a Look to the Future Jackson Center, PA, July 12, 2022. Halberd Corporation (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. The accomplishments for the Second Quarter ending June 30, 2022, are as follows: 2Q ACHIEVEMENTS Added an animal testing expert (DVM/PhD) to our list of scientific consultants to plan and execute extensive animal testing of Halberd’s patented extracorporeal process for the ...